Mereo BioPharma Group plc

Transaction in Own Shares • Dec 3, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5578V

Mereo BioPharma Group plc

03 December 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of PDMR Dealing

London, December 03, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on December 02, 2019, John Richard, Head of Corporate Development, purchased 3500 American Depositary Shares (ADSs) at an aggregated price of USD 2.201 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

PURCHASE OF ADS

c)

Price(s) and volume(s)

Price(s)	Volume(s)
USD 2.25	400
USD 2.20	2269
USD 2.19	547
USD 2.19	100
USD 2.18	1
USD 2.16	1
USD 2.15	182

d)

Aggregated information:  volume, Price

Aggregated volume: 3500

Aggregated price: USD2.201

e)

Date of the transaction

2019-12-02

f)

Place of the transaction

XNMS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBLBDDXUGBGCX